

**RiskMaps**  
**Multiple Myeloma**  
**June 25, 2007**

Ken Makowka

Wilton, CT

Fairfield County MM Support Group

# Multiple Myeloma

- 750,000 Cases Worldwide
- 16,000 (est.) New Cases Yearly in the US
- 54% Male, 46% Female
- 9.5 cases per 100,000 African Americans
- 4.1 cases per 100,000 Caucasians
- 50,000 Survivors in the US as of 2005
- 99% of Patients are over 40
- 50% of Patients are over 71
- Trend is towards younger patients

# Multiple Myeloma

- Myeloma is a cancer of the Plasma Cells
- #2 Blood Cancer
- Incurable but treatable
- “The bad news is that you have cancer, the good news is that you Have Myeloma”
- Bone marrow is source of stem cells and drugs that are tried on Myeloma cells have a very quick response time vs. Leukemia or Lymphoma cells.

# Myeloma Treatments

- Currently 316 trials available for Myeloma patients.
- New drugs recently approved- Velcade, Revlimid, Thalimid, Doxil.
- Bisphosphonates- Aredia, Zometa- ONJ

# Research on Riskmaps

- 12 Myeloma Patients contacted- all currently or previously (last 12 months) on Revlimid or Thalimid from Celgene.
- Only one, an internist, had heard of Riskmaps. It was not for a Myeloma related drug.

# RiskMaps Research-cont.

- One International foundation contacted- no knowledge of program.
- Four physicians contacted- two internists had experience with Lotronex, oncologists had no prior knowledge. “Can see need for control, but found system onerous”.

# Myeloma Drug Programs

- Cannot confirm if any Myeloma drugs are in RiskMaps program.
- Thalomid- S.T.E.P.S. Program
- Revlimid- RevAssist Program
  
- Physician & Patient Registration
- Pharmacy Registration
- Monthly call-in to Celgene: 4-6 auto questions
- Release of script to Pharmacy- 7 day pickup

# RiskMaps Impact Myeloma

- Currently unknown to population involved
- Definite need to educate Doctors, NPs, Nurses, and ultimately, the patient.
- Will a full RiskMaps defined drug, especially a new drug, influence a physician's to use or not utilize it, because of the paperwork or worse, lack of understanding of the program.